|05-06-2012, 07:37 AM||#1|
Join Date: Sep 2004
Clinical outcome of autologous peripheral blood stem cell transplantation in OSMS
Ann Hematol. 2011 Mar;90(3):343-8. Epub 2010 Sep 25.
Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
Xu J, Ji BX, Su L, Dong HQ, Sun WL, Wan SG, Liu YO, Zhang P, Liu CY.
Department of Hematology, Xuan Wu Hospital, Capital Medical University, No. 45 Changchun Street, Xuan Wu District, Beijing, China. email@example.com
To evaluate clinical outcomes of autologous peripheral blood stem cell transplantation (APBCST) between opticospinal multiple sclerosis (OSMS) and conventional multiple sclerosis (CMS) during disease progressive stage in a Chinese population. Thirty-six secondary progressive MS patients, among whom 21 were with OSMS and 15 with CMS, underwent APBSCT and were followed up for an average of 48.92 months (range, 10-91 months). Peripheral blood stem cells were obtained by leukapheresis after mobilization with granulocyte colony-stimulating factor. Modified BEAM conditioning regimen (Tiniposide, melphalan, carmustin, and cytosine arabinoside) were administered. Outcomes were evaluated using the expanded disability status scale (EDSS). No maintenance treatment was administered if there was no disease progression. No treatment-related mortality occurred. Among the 36 patients, one OSMS patient dropped during the follow-up. Among the 22 relapse-free patients, 20 were with continuous neurological improvement without any relapse events, and two remained in neurologically stable states. Among the 13 relapse patients, seven had experienced of neurological relapse, but with no progression during the follow-up period; and six experienced neurological deterioration after transplantation and needed further immunosuppressant treatment. The confirmed relapse-free survival rate was 62.9% and progression-free survival rate was 83.3% after 91 months according to Kaplan and Meier survival curves. Eleven of the 20 OSMS patients (55%) and two of the 15 CMS patients (13.3%) stayed in disease active group (P = 0.014). For the 20 OSMS patients, the overall EDSS score decreased significantly after transplantation (P = 0.016), while visual functions had no significant improvement (P = 0.716). Progressive OSMS has a higher relapse rate than CMS following APBSCT.
“As the cast of villains in SCI is vast and collaborative, so too must be the chorus of hero's that rise to meet them” Ramer et al 2005
|Thread||Thread Starter||Forum||Replies||Last Post|
|Immune ablation followed by autologous hematopoietic stem cell transplantation||wildwilly||Transverse Myelitis Research||0||04-24-2009 01:13 PM|
|Autologous haematopoietic stem-cell transplantation in multiple sclerosis||wildwilly||Multiple Sclerosis Research||0||07-11-2008 12:55 PM|
|Intraspinal tumor treated with autologous stem cell transplantation||Leif||Tranverse Myelitis, Multiple Sclerosis, Non-traumatic SCI||3||12-26-2006 10:05 AM|
|Autologous Stem-Cell Transplantation leads to Cure of Amyloidosis in 40% of Cases||Faye||Cure||1||01-20-2004 11:21 AM|
|Roelofs, et al. (2003). Homeostasis of telomere length rather than telomere shortening after allogeneic peripheral blood stem cell transplantation.||Wise Young||Stem Cell Research||0||12-18-2002 09:29 PM|